(1) Introduction: In response to patient concerns about breast cancer recurrence, increased use of breast magnetic resonance imaging and genetic testing, and advancements in breast reconstruction techniques, mastectomy rates have been observed to rise over the last decade. The aim of the study is to compare the outcomes of prepectoral and subpectoral implants and long-term, dual-stage resorbable mesh-based breast reconstructions in mutation carriers (prophylactic surgery) and breast cancer patients. (2) Patients and methods: This retrospective, two-center study included 170 consecutive patients after 232 procedures: Prepectoral surgery was performed in 156 cases and subpectoral was performed in 76. (3) Results: Preoperative chemotherapy was associated with more frequent minor late complications (p < 0.001), but not major ones (p = 0.101), while postoperative chemotherapy was related to more frequent serious (p = 0.005) postoperative complications. Postoperative radiotherapy was associated with a higher rate of minor complications (31.03%) than no-radiotherapy (12.21%; p < 0.001). Multivariate logistic regression found complications to be significantly associated with an expander (OR = 4.43), skin-reducing mastectomy (OR = 9.97), therapeutic mastectomy vs. risk-reducing mastectomy (OR = 4.08), and postoperative chemotherapy (OR = 12.89). Patients in whom prepectoral surgeries were performed demonstrated significantly shorter median hospitalization time (p < 0.001) and lower minor complication rates (5.77% vs. 26.32% p < 0.001), but similar major late complication rates (p = 0.915). (4) Conclusions: Implant-based breast reconstruction with the use of long-term, dual-stage resorbable, synthetic mesh is a safe and effective method of breast restoration, associated with low morbidity and good cosmesis. Nevertheless, prospective, multicenter, and long-term outcome data studies are needed to further evaluate the benefits of such treatments.

No abstract

Introduction Currently, more and more cases of breast cancer are detected in the early stages of advancement. Removal of the minimum required tissue volume ensures that the proper shape of the breast is maintained. On the other hand, it is important to get negative tissue margins. Objective To present your own experience with the use of preoperative breast tumor determination using the Magseed marker. Material and methods On the eve of the procedure, a Magtrace magnetic marker was administered to determine the lymph nodes and, under ultrasound control, a Magseed magnetic marker to the tumor, and the site of the lesion was marked with a skin marker as the operated site. Before the skin incision, the lesion was located using intraoperative ultrasound and the Sentimag probe. After the tumor was excision, the presence of the marker was confirmed in the preparation using the magnetic method and the compatibility of the ultrasound image before and after the procedure. The results of the research group were 23 patients. Radicality of the procedure was achieved in 20 patients (87%). To assess the size of the preparation and tumor, a formula from the work of Angarita et al. on the volume of the ellipsoid was used. It was assessed what part of the excised preparation was a tumor marked using the Magseed marker. Cohorts of 11 patients at the beginning and end of the evaluated group were compared, showing a significant increase in this parameter. Together with the learning curve, you can identify the tumor much more precisely and save healthy breast tissues by improving the aesthetic effect in the breast range. Conclusions The method of localization of non-pallpatory lesions in the mammary gland using the Magseed marker is simple to use, and the high detection rate directly translates into a reduction in the percentage of non-radical treatments in the case of sparing treatment.

Introduction. Triple-negative breast cancer (TNBC) is characterized by a lack of oestrogen, progesterone and human epidermal growth factor receptors. It is the one of most heterogeneous and highly-aggressive breast cancers, resulting in fast progression. In humans, the lymphocyte activation gene 3 (LAG3) is located on chromosome 12p13 and encodes an immune-regulatory molecule. The aim of the study was to perform a molecular analysis of LAG3 gene polymorphisms. Material and method. The presence of single-nucleotide polymorphisms (SNPs) at rs2365094 was determined in 30 TNBC patients and 30 healthy controls using a polymerase chain reaction (PCR) and commercially-available TaqMan SNP Genotyping Assays. SNP status was then compared with the clinical outcome. Results. The allelic alterations in LAG3 gene SNP in rs2365094 appear to have no influence on the clinicopathological picture among TNBC patients. The carriage rate for a single allele did not differ significantly between patients and controls. Conclusions. No significant relationship was observed between the rs2365094 SNP status and clinicopathological determinants.

Introduction: Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen, progesterone and human epidermal growth factor receptors. It is the one of most heterogeneous and highly-aggressive breast cancers, resulting in fast progression. In humans, the LAG3 gene is located on chromosome 12p13 and encodes an immune-regulatory molecule. LAG3 gene polymorphisms may influence the clinicopathological picture. Aim: The aim of the study was to perform a molecular analysis of LAG3 gene polymorphisms Method: The presence of single-nucleotide polymorphisms (SNPs) at rs2365094 was determined in 30 TNBC patients and 30 healthy controls using polymerase chain reaction (PCR) and commercially-available TaqMan SNP Genotyping Assays. SNP status was the compared with clinical outcome. Result: The allelic alterations in LAG3 gene SNP in rs2365094 appear to have no influence on the clinicopathological picture among TNBC patients. The carriage rate for a single allele did not differ significantly between patients and controls. Conclusion: No significant relationship was observed between rs2365094 SNP status and clinicopathological determinants. However, one aim of this work was to identify biomarkers that may serve as criteria for drug combination regimens. When used in combination with other genetic biomarkers, LAG3 gene SNP may be used for risk stratification of patients with TNBC.